Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) can significantly reduce the incidence and risk of death from multiple cancers, but their long-term use for chemoprevention is not recommended because of potentially fatal toxicities resulting from cyclooxygenase (COX) inhibition. However, the mechanism responsible for their tumor cell growth inhibitory activity may not require COX inhibition, which suggests that NSAID derivatives lacking COX inhibitory activity have potential for improved safety and efficacy. Cyclic guanosine monophosphate phosphodiesterase (cGMP PDE) inhibition appears to be an important mechanism based on previous studies with the NSAID, sulindac. Here we characterize a novel sulindac derivative referred to as sulindac benzylamine (SBA) that does not inhibit COX-1 or COX-2, yet potently inhibits the growth and induces the apoptosis of human colon tumor cells. This activity is closely associated with cGMP PDE inhibition given that SBA can inhibit cGMP hydrolysis in colon tumor cell lysates, increase intracellular cGMP levels, and activate cGMP-dependent protein kinase G (PKG) at concentrations that suppress tumor cell growth and induce apoptosis. The cGMP-specific PDE isozyme, PDE5 is selectively inhibited by SBA and elevated in colon tumor cells compared with normal colonocytes that display reduced sensitivity to SBA. PKG activation by SBA is associated with the reduction of nuclear β-catenin levels and inhibition of Tcf transcriptional activity in which the anti-apoptosis gene, survivin is suppressed. These events preceded apoptosis induction by SBA and appear to result from the rapid elevation of intracellular cGMP levels following cGMP PDE inhibition. Transient transfection with PDE5 siRNA reduced PDE5 protein expression in both human normal (NCM460) colonocytes and colon tumor cell lines (HT29 and HCT116), but only suppressed cGMP PDE activity in the tumor cells, likely because of low PDE5 levels and/or the presence of other cGMP degrading isozymes in normal colonocytes. In accord, PDE5 siRNA selectively suppressed growth and induced apoptosis of colon tumor cells, but not normal colonocytes. Colon tumor cells transfected with PDE5 siRNA also displayed reduced β-catenin levels and Tcf transcriptional activity as well as increased sensitivity to SBA treatment. Finally, molecular modeling studies suggest that SBA directly interferes with cGMP binding within the catalytic domain of PDE5. However, additional cGMP degrading PDE isozymes may either be responsible for or contribute to the sensitivity of tumor cells to SBA given that PDE5 selective inhibitors (e.g. sildenafil) do not effectively suppress colon tumor cell growth. These results lead us to conclude that cGMP PDE inhibition is an important molecular target for cancer chemoprevention, although further studies are necessary to identify key cGMP degrading isozymes involved in tumorigenesis. This research was supported NIH grants, NCI 1R01CA131378 and 1R01CA148817-01A1. Citation Format: Gary A. Piazza, Nan Li, Gary D. Bernard, Xi Chen, Adam B. Keeton, Yaguang Xi, Bing Zhu, Wei Zhang, Alexandra Fajardo, Veronica Ramirez, Sara Sigler, Kevin Lee, Claire Cawthon, Evrim Gurpinar, Maya A. Brownby, Heather N. Tinsely, Ashraf Abadi, William Grizzle. Cyclic GMP phosphodiesterase: A molecular target for cancer chemoprevention. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B59.

Abstract 2028: PDE3A modulation for cancer therapy

Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death

Abstract 1397: the Regulation of DNMT3B Expression by Lncrna-Ncrms in Cancer

Abstract 4360: Validation of phosphodiesterase 10A as a cancer target

Structure of PDE3A-SLFN12 Complex and Structure-Based Design for a Potent Apoptosis Inducer of Tumor Cells

Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12

Abstract 6064: Discovery of potent and selective EP300 degraders with anti-cancer activity

Abstract C182: Phosphodiesterase 10: A novel cancer target.

Abstract 1773: Phosphodiesterase 10A: A novel target for selective inhibition of colon tumor cell growth and Wnt/β-catenin signaling

Abstract B59: Cyclic GMP phosphodiesterase: A molecular target for cancer chemoprevention

Complex Structure of PDE3A–SLFN12 and Structure-based Molecular Glue Design for Apoptosis of Tumor Cells

Abstract 2016: Combined targeting of epigenetic mechanisms has superior efficacy against human mantle cell lymphoma cells

Abstract 2322: β-catenin-dependent TCF/LEF transcriptional regulation of phosphodiesterase expression in colon cancer cells

Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer

Abstract 1833: A large-scale synthetic lethal RNAi screening identifies unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma

An Alkaloid Initiates Phosphodiesterase 3A-Schlafen 12 Dependent Apoptosis Without Affecting the Phosphodiesterase Activity.

Abstract MP265: The Role Of Phosphodiesterase 10a In Tumor Growth And Doxorubicin-induced Cardiotoxicity

Abstract 4533: in Vivo Activation of the P53 Pathway Leading to Tumor Regression by a Novel and Potent HDM2 Antagonist SCH 1450206

Abstract 3168: Amphiphilic dendrimer-mediated siRNA delivery for precision regulation of cAMP pathway in cancer cells

Abstract 1762: Phosphodiesterase 10, a novel target for colorectal cancer therapeutics

Abstract 1140: Characterization of a novel PDE10 inhibitor in lung tumor cells and an orthotopic mouse model of lung cancer